Skip to main content

Drug Interactions between Bethkis and cisplatin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

tobramycin CISplatin

Applies to: Bethkis (tobramycin) and cisplatin

GENERALLY AVOID: Combining cisplatin and aminoglycosides may increase the risk of renal toxicity. Both cisplatin and aminoglycosides have been reported to cause renal magnesium wasting. The exact mechanism of the interaction is unknown.

MANAGEMENT: In patients currently receiving cisplatin therapy, the use of less nephrotoxic antimicrobials is preferable. If cisplatin and an aminoglycoside must be used together, renal function and serum magnesium should be monitored carefully.

References (7)
  1. Dentino M, Luft FC, Yum MN, et al. (1978) "Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man." Cancer, 41, p. 1274-81
  2. Hass A, Anderson L, Lad T (1983) "The influence of aminoglycosides on the nephrotoxicity of cis-diamminedichlorophatinum in cancer patients." J Infect Dis, 147, p. 363
  3. Patel R, Savage A (1979) "Symptomatic hypomagnesemia associated with gentamicin therapy." Nephron, 23, p. 50-2
  4. Stewart CF, Christensen ML, Crom WR, Evans WE (1984) "The effect of cisplatin therapy on gentamicin pharmacokinetics." Drug Intell Clin Pharm, 18, p. 512
  5. Blachley JD, Hill JB (1981) "Renal and electrolyte disturbances associated with cisplatin." Ann Intern Med, 95, p. 628-32
  6. Christensen ML, Stewart CF, Crom WR (1989) "Evaluation of aminoglycoside disposition in patients previously treated with cisplatin." Ther Drug Monit, 11, p. 631-6
  7. (2018) "Product Information. Arikayce (amikacin liposome)." Insmed Incorporated

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer